

醫師 您好

邀請您參加 3 月 24 日晚間 7 點舉辦之 **MBC TALKS** 系列視訊會議:

Optimizing CDK4&6 Inhibitor Treatment Outcomes

本次將由 **Prof. Eva Ciruelos(西班牙)** 與 **Prof. Mark Thill(德國)** 共同探討針對 endocrine resistance 病人族群的 CDK4&6i 臨床試驗，並藉由一臨床案例討論治療方案。**Maria Noblet 專科護理師(英國)** 也將分享病人服用 VERZENIO 之前的衛教諮詢與常見副作用處置。
期待您的參與並與講者進行線上即時Q&A。

Agenda

- Abemaciclib treatment, side effects management and different CDK4&6i trials - **20 min**
- Panel Discussion and live Q&A - **40 min**



Date:

03/24 (Wed)

[+ 加入行事曆](#)



Session 1:

19:00-20:00 (台灣時間)

12:00 PM CET (中歐時間)

- 請於註冊頁面填寫中文姓名、電子信箱、台灣乳房醫學會之會員編號
 - 務必填寫正確資料並完整觀看線上會議以確保取得學分資格
- * 學會擁有最終學分認可之權利



Prof. Eva Ciruelos

Coordinator of Multidisciplinary breast cancer Unit at the Hospital HM Puerta del Sur. Medical oncologist of breast cancer Unit at the Hospital 12 de Octubre and an Associate Professor of Medicine at the Universidad Complutense de Madrid Facultad de Medicina. President of the Solid Tumor Intensification Group of Breast Cancer Research. Dr. Ciruelos's research interest focus on breast tumor.



Prof. Marc Thill

Head of the Gynecology and Gynecologic Oncology and Obstetrics, Breast Cancer Center and Gynecological Cancer Center at the Agaplesion Markus Hospital in Frankfurt am Main, Germany. Specialized in gynecological oncology and is a certified breast and gynecological reconstructive surgeon. Study director, coordinator and principal investigator on numerous national and international clinical trials.



Maria Noblet R.N.

Consultant Nurse at Portsmouth Hospitals NHS Trust. Nursing member in National Clinical Reference Group for Breast cancer. Chair of RCN breast care nursing forum providing leadership and influencing the national agenda on breast cancer nursing issues. Participated in the development of the first specialist educational programme for specialist breast care nursing (A11).